|
||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original Article |
Correspondence to: Tak W. Mak, Ontario Cancer Institute/Amgen Institute, 620 University Ave., Ste. 706, Toronto, Ontario M5G 2C1, Canada. Tel:416-204-2236 Fax:416-204-5300 E-mail:tmak{at}amgen.com.
Interferon (IFN) regulatory factor (IRF)-2 was originally described as an antagonist of IRF-1mediated transcriptional regulation of IFN-inducible genes. IRF-1-/- mice exhibit defective T helper type 1 (Th1) cell differentiation. We have used experimental leishmaniasis to show that, like IRF-1-/- mice, IRF-2-/- mice are susceptible to Leishmania major infection due to a defect in Th1 differentiation. Natural killer (NK) cell development is compromised in both IRF-1-/- and IRF-2-/- mice, but the underlying mechanism differs. NK (but not NK+ T) cell numbers are decreased in IRF-2-/- mice, and the NK cells that are present are immature in phenotype. Therefore, like IRF-1, IRF-2 is required for normal generation of Th1 responses and for NK cell development in vivo. In this particular circumstance the absence of IRF-2 cannot be compensated for by the presence of IRF-1 alone. Mechanistically, IRF-2 may act as a functional agonist rather than antagonist of IRF-1 for some, but not all, IFN-stimulated regulatory element (ISRE)-responsive genes.
Key Words: interferon regulatory factor, Th1, natural killer cells, Leishmania, interleukin 15
This article has been cited by other articles:
| TABLE OF CONTENTS |
|